QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Omeros Corporation (OMER)

Healthcare

No action
Fundamental
3
Sentiment
2
Technical
2

Do Nothing: qualitativeScore is 2 (below the required floor of 3) — the upstream qualitative screen flagged a serious overhang (2026-10-16 CHMP negative opinion on narsoplimab, sentiment delta −0.41) and the shadow sum-gate is unavailable (flag false), so no long is admitted; the chart independently fails the entry floor (technicalScore 2 < 3), no pullback limit qualifies (price 16.35 < SMA50 18.36 with MACD −0.18 < 0 is countertrend), and no breakout stop qualifies (no qualifying base/high to trigger above at a ≥3 score).

Analysis as of 2026-10-19· more than 2 trading days ago

Company overview

Omeros Corporation is a biopharmaceutical company focused on developing therapies for inflammatory conditions, immune system-related cancers, and addiction disorders. Its lead product, narsoplimab, is approved for HSCT-TMA and is in trials for other conditions. The company also has a diverse pipeline of clinical and preclinical candidates.

Fundamental

fair
Fundamental3
Mixed but improving

Omeros has transitioned to a commercial-stage company with a successful product launch, but its valuation assumes execution and earnings are non-recurring.

Mixed but improving: Omeros is a newly commercial-stage biotech whose YARTEMLEA launch ($38.4 million of first-half 2026 sales, Q2 operating breakeven, positive Q2 operating cash flow) is real and is funded by $132.0 million of cash with the debt stack nearly cleared — but reported earnings are dominated by the zaltenibart sale gain and 2029 Notes derivative marks, book equity is negative, and the valuation (about 31 times sales, negative DCF values) already assumes a successful single-product ramp. Watchlist: payer coverage and launch durability are the swing factors.

Sentiment

weak
Sentiment2
Post-shock digestion

Sentiment is negatively impacted by a regulatory setback in Europe, with no immediate catalysts to offset the decline.

Omeros is dominated by a single fresh, regulator-confirmed negative: the EMA's CHMP upheld its negative opinion on narsoplimab in TA-TMA on 2026-10-16, the stock fell 13.78% that session, and the media delta deteriorated determinately from a mildly positive baseline (+0.26) to a mixed-negative scoring window (−0.145, roughly −0.41). No market-rewarded bullish leg qualifies in the actionable window (analyst reiterations, a recycled CMS reimbursement story and a fading August earnings beat do not), the Red-Flag Screen is free of severe flags but a moderate sharp-deterioration flag fired, so a moderate red-flag cap applied at a ceiling of 3 — and the deteriorating-sentiment/no-positive-catalyst row is the row that actually matches the evidence.

Technical

weak
Technical2
Post-shock downtrend

The stock is in a downtrend with weak technical indicators, lacking a setup for a long position.

OMER is in a post-shock downtrend. After the 2026-10-16 regular-session gap and −9.7% close (the CHMP re-examination negative opinion on the narsoplimab MAA), price closed 2026-10-19 at 16.35, below SMA20 (19.01), SMA50 (18.36), EMA9 (18.00), EMA21 (18.43), WMA9/21 (17.96/18.57), DEMA14 (17.80) and TEMA14 (17.18); only the SMA200 (13.33) still sits beneath price. MACD is negative and widening (−0.18 line / 0.22 signal / −0.39 histogram), RSI14 36.66 and Williams %R −88.61 show oversold pressure but no confirmed reversal bar, ADX14 19.68 is weak and has fallen from 26.55 on 2026-10-05, and ATR14 0.95 (5.81% of price) flags elevated volatility. The 2026-10-19 session stabilised (+0.93%, close 16.35 vs VWAP 16.33) but on lighter volume than the decline. Chart quality is bounce-only → technicalScore 2. Independently of the chart, the qualitative floor (qualitativeScore 2) hard-blocks any new long.

You’re looking at 2026-10-19 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.